|
|
Blood, 15 June 2005, Vol. 105, No. 12, pp. 4553-4560.
Prepublished online as a Blood First Edition Paper on February 22, 2005; DOI 10.1182/blood-2004-12-4750.
 Previous Article | Table of Contents | Next Article 
REVIEW IN TRANSLATIONAL HEMATOLOGY
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
Daniel Re,
Roman K. Thomas,
Karolin Behringer, and
Volker Diehl
From the Department I of Internal Medicine and The Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; The Burnham Institute, John Reed Laboratory, La Jolla, CA; and the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Reclassification of Hodgkin disease as Hodgkin lymphoma (HL) represents a milestone in the lymphoma field, awarding recent insights in the molecular biology of Hodgkin and Reed-Sternberg (H-RS) cells and their environment. This review summarizes antiapoptotic and proproliferative pathways involved in the pathogenesis of this disease with the ultimate goal of translating laboratory knowledge into clinical decision making. The focus is on potential targets and novel drugs, which are discussed in the context of the complex biology of HL. Considering that HL patients are more likely to die from acute and late treatment-related toxicities than from HL itself, the introduction of targeted, biologically based therapies for HL patients with palliative and eventually curative intention might be justified. (Blood. 2005;105:4553-4560)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. J. Salipante, M. E. Mealiffe, J. Wechsler, M. M. Krem, Y. Liu, S. Namkoong, G. Bhagat, T. Kirchhoff, K. Offit, H. Lynch, et al.
Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells
PNAS,
September 1, 2009;
106(35):
14920 - 14925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Boll, F. Eltaib, K. S. Reiners, B. von Tresckow, S. Tawadros, V. R. Simhadri, F. J. Burrows, K. Lundgren, H. P. Hansen, A. Engert, et al.
Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-{kappa}B and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell-Mediated Cytotoxicity
Clin. Cancer Res.,
August 15, 2009;
15(16):
5108 - 5116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-C. Chang, Y. Chang, D. Jones, and I.-J. Su
Aberrant Expression of Cyclin A Correlates With Morphogenesis of Reed-Sternberg Cells in Hodgkin Lymphoma
Am J Clin Pathol,
July 1, 2009;
132(1):
50 - 59.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Buglio, G. V. Georgakis, S. Hanabuchi, K. Arima, N. M. Khaskhely, Y.-J. Liu, and A. Younes
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
Blood,
August 15, 2008;
112(4):
1424 - 1433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl
Hodgkin's Disease -- From Pathology Specimen to Cure
N. Engl. J. Med.,
November 8, 2007;
357(19):
1968 - 1971.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Diepstra, G. W. van Imhoff, H. E. Karim-Kos, A. van den Berg, G. J. te Meerman, M. Niens, I. M. Nolte, E. Bastiaannet, M. Schaapveld, E. Vellenga, et al.
HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma
J. Clin. Oncol.,
July 20, 2007;
25(21):
3101 - 3108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Horning
Risk, Cure and Complications in Advanced Hodgkin Disease
Hematology,
January 1, 2007;
2007(1):
197 - 203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sanchez-Aguilera, C. Montalban, P. de la Cueva, L. Sanchez-Verde, M. M. Morente, M. Garcia-Cosio, J. Garcia-Larana, C. Bellas, M. Provencio, V. Romagosa, et al.
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma
Blood,
July 15, 2006;
108(2):
662 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
